0.9245

0.49% 0.0045

After Hours: .92 -0.0045 -0.49%

Mira Pharmaceuticals Inc (MIRA)

Overview News Price History Discussions Forecast

Mira Pharmaceuticals Inc stock is traded at $0.9245, with a volume of 97,844. It is up +0.49% in the last 24 hours and down -5.68% over the past month. Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.

Previous Close:

$0.92

Open:

$0.95

24h Volume:

97,844

Relative Volume:

0.84

Market Cap:

$38.85M

Revenue:

Net Income/Loss:

$-31.37M

P/E Ratio:

-0.6429

EPS:

-1.438

Net Cash Flow:

$-4.23M

1W Performance:

-2.15%

1M Performance:

-5.68%

6M Performance:

-37.53%

1Y Performance:

-22.96%

1-Day Range:

$0.904

$0.95

1-Week Range:

$0.8961

$0.99

52-Week Range:

$0.8961

$2.45

Mira Pharmaceuticals Inc Stock (MIRA) Company Profile

Name

Mira Pharmaceuticals Inc

Sector

Healthcare (1096)

Industry

Drug Manufacturers - General (20)

Phone

813-369-5150

Address

1200 BRICKELL AVENUE, MIAMI

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

MIRA's Discussions on Twitter

Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MIRA Mira Pharmaceuticals Inc	0.9245	38.85M	0	-31.37M	-4.23M	-1.438
LLY Lilly Eli Co	1,188.58	1.06T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	256.98	618.61B	96.36B	21.04B	17.80B	8.6488
ABBV Abbvie Inc	248.08	438.31B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	123.54	305.12B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	154.05	293.94B	54.66B	13.58B	16.05B	7.0171

Mira Pharmaceuticals Inc Stock (MIRA) Latest News

Jul 10, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 10, 2026

MIRA Pharmaceuticals (NASDAQ:MIRA) Advances Pain Program - Kalkine Media

Jul 10, 2026

MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 - Investing.com

Jul 10, 2026

MIRA Pharmaceuticals announces positive preclinical results for MIRA-55 - TipRanks

Jul 10, 2026

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire

Jul 10, 2026

MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55 - Stock Titan

Jul 10, 2026

Experimental MIRA-55 pill shows brain and liver reach in pain studies - Stock Titan

Jul 10, 2026

Jul 07, 2026

Mira reports results on optimized oral formulation of SKNY-1 - BioWorld News

Jul 07, 2026

Jul 06, 2026

Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies - Moomoo

Jul 06, 2026

MIRA Reports Positive Preclinical Data for SKNY-1 Program - TipRanks

Jul 06, 2026

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire

Jul 06, 2026

MIRA Pharmaceuticals (MIRA) reports promising SKNY-1 preclinical pharmacokinetic and behavioral data - Stock Titan

Jul 06, 2026

MIRA's obesity-and-addiction drug shows brain and liver exposure - Stock Titan

Jul 06, 2026

MIRA SEC FilingsMira Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 06, 2026

Jul 02, 2026

MIRA Q3 2025 Earnings: EPS Beats Estimates by 26.47% as Pre-Revenue Biotech Focuses on Pipeline ProgressEPS Miss Report - dars.gov.et

Jul 02, 2026

What's going on with MIRA Pharma stock Tuesday? - MSN

Jul 02, 2026

MIRAMira Pharmaceuticals Inc Options - Finviz

Jul 02, 2026

Jun 29, 2026

MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Whalen Matthew Pratt - Moomoo

Jun 29, 2026

MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MacPherson Edward Cloustonmoomoo - Moomoo

Jun 29, 2026

MIRA Pharmaceuticals, Inc.(NasdaqCM:MIRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 29, 2026

MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Index - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Price to earnings forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView

Jun 27, 2026

Jun 26, 2026

Enterprise value to revenue forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView

Jun 26, 2026

Price to sales forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView

Jun 26, 2026

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC - Black Hills Pioneer

Jun 26, 2026

MIRA Pharmaceuticals (NASDAQ:MIRA) Reports Positive Preclinical Data for Mira-55 in Chronic Inflammatory Pain - grafa.com

Jun 25, 2026

Mira Pharmaceuticals reports preclinical data on pain drug candidate - Investing.com

Jun 25, 2026

MIRA Pharmaceuticals Advances Mira-55 for Chronic Pain Relief - GuruFocus

Jun 25, 2026

Mira Pharmaceuticals reports preclinical data on pain drug candidate By Investing.com - Investing.com Australia

Jun 25, 2026

MIRA Unveils Differentiated Preclinical Data for Mira-55 - TipRanks

Jun 25, 2026

MIRA’s Mira-55 eases anxiety in preclinical tests, unlike THC - Stock Titan

Jun 25, 2026

MIRA reports preclinical Mira-55 data showing distinct mechanism, anxiolytic activity vs THC - TradingView

Jun 25, 2026

MIRA Pharmaceuticals (NASDAQ: MIRA) highlights differentiated Mira-55 preclinical profile vs. THC - Stock Titan

Jun 25, 2026

Jun 22, 2026